Please assess the completion status of the following clinical trial:

Trial Title: Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve~* Age older than 18 years old~* Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Taqman HCV Monitor v2.0, Roche Diagnostics) with dynamic range 25 \~ 391000000 IU/ml~* HCV genotype 2 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)~* Serum alanine aminotransferase levels above the upper limit of normal with 6 months of enrollment~* A liver biopsy consistent with the diagnosis of chronic hepatitis C~Exclusion Criteria:~* Anemia (hemoglobin \< 13 grams per deciliter for men and \< 12 grams per deciliter for women)~* Neutropenia (neutrophil count \< 1,500 per cubic milliliter)~* Thrombocytopenia (platelets \< 90,000 per cubic milliliter)~* Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic alcohol abuse (daily consumption \> 20 grams per day)~* Decompensated liver disease (Child-Pugh class B or C)~* Serum creatinine level more than 1.5 times the upper limit of normal~* Autoimmune liver disease~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to use contraception~* Unwilling to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peg-IFN + WB RBV for 16 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
- Peg-IFN + LD RBV for 16 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
- Peg-IFN + WB RBV for 24 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
- Peg-IFN + WB RBV for 48 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
- Peg-IFN + LD RBV for 24 weeks (Type: ACTIVE_COMPARATOR): Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR

Based on this trial design, predict the completion outcome and termination type (if applicable).